Tanja Langsenlehner1, Eva-Maria Thurner2, Sabine Krenn-Pilko2, Uwe Langsenlehner3, Tatjana Stojakovic4, Armin Gerger5, Martin Pichler5. 1. Department of Therapeutic Radiology and Oncology, Comprehensive Cancer Center Graz, Medical University of Graz, Auenbruggerplatz 32, 8036, Graz, Austria. tanja.langsenlehner@medunigraz.at. 2. Department of Therapeutic Radiology and Oncology, Comprehensive Cancer Center Graz, Medical University of Graz, Auenbruggerplatz 32, 8036, Graz, Austria. 3. Division of Internal Medicine, Outpatient Department Graz, Graz, Austria. 4. Clinical Institute of Medical and Chemical Laboratory Diagnostics, Comprehensive Cancer Center Graz, Medical University of Graz, Graz, Austria. 5. Division of Clinical Oncology, Department of Medicine, Comprehensive Cancer Center, Medical University of Graz, Graz, Austria.
Abstract
PURPOSE: Recent studies have expanded the concept that the systemic inflammatory response has an important role in the progression of several solid tumors. The neutrophil-to-lymphocyte ratio (NLR), an easily determinable marker of systemic inflammation, has been associated with clinical outcome in various cancer entities. In the present study, we validated the prognostic relevance of an elevated NLR in a cohort of European prostate cancer patients. METHODS: Data from 415 consecutive prostate cancer patients treated with 3D conformal radiotherapy at a single tertiary academic center from 1999 to 2007 were included in this retrospective study. Clinical progression-free survival (PFS), distant metastases-free survival (DMFS), and overall survival (OS) were assessed using the Kaplan-Meier method. To evaluate the prognostic relevance, univariate and multivariate Cox regression models were performed for each end point. RESULTS: Based on previously published studies, an NLR ≥ 5 was selected as cutoff value for external validation. Multivariate analysis identified an increased NLR as an independent prognostic factor for clinical PFS [hazard ratio (HR) 3.09, 95 % CI 1.64-5.82, p < 0.001], DMFS (HR 3.51, 95 % CI 1.80-6.85, p < 0.001), and OS (HR 2.16, 95 % CI 1.17-3.99, p = 0.013). CONCLUSION: The NLR seems to represent an independent prognostic marker and should be considered for future individual risk assessment in patients with prostate cancer.
PURPOSE: Recent studies have expanded the concept that the systemic inflammatory response has an important role in the progression of several solid tumors. The neutrophil-to-lymphocyte ratio (NLR), an easily determinable marker of systemic inflammation, has been associated with clinical outcome in various cancer entities. In the present study, we validated the prognostic relevance of an elevated NLR in a cohort of European prostate cancerpatients. METHODS: Data from 415 consecutive prostate cancerpatients treated with 3D conformal radiotherapy at a single tertiary academic center from 1999 to 2007 were included in this retrospective study. Clinical progression-free survival (PFS), distant metastases-free survival (DMFS), and overall survival (OS) were assessed using the Kaplan-Meier method. To evaluate the prognostic relevance, univariate and multivariate Cox regression models were performed for each end point. RESULTS: Based on previously published studies, an NLR ≥ 5 was selected as cutoff value for external validation. Multivariate analysis identified an increased NLR as an independent prognostic factor for clinical PFS [hazard ratio (HR) 3.09, 95 % CI 1.64-5.82, p < 0.001], DMFS (HR 3.51, 95 % CI 1.80-6.85, p < 0.001), and OS (HR 2.16, 95 % CI 1.17-3.99, p = 0.013). CONCLUSION: The NLR seems to represent an independent prognostic marker and should be considered for future individual risk assessment in patients with prostate cancer.
Entities:
Keywords:
Inflammation; Neutrophil-to-lymphocyte ratio; Prognosis; Prostate cancer
Authors: K Shafique; M J Proctor; D C McMillan; K Qureshi; H Leung; D S Morrison Journal: Prostate Cancer Prostatic Dis Date: 2011-11-29 Impact factor: 5.554
Authors: Yago Nieto; Samia Nawaz; Elizabeth J Shpall; Scott I Bearman; James Murphy; Roy B Jones Journal: Clin Cancer Res Date: 2004-04-15 Impact factor: 12.531
Authors: Paulo C Rodriguez; Marc S Ernstoff; Claudia Hernandez; Michael Atkins; Jovanny Zabaleta; Rosa Sierra; Augusto C Ochoa Journal: Cancer Res Date: 2009-02-05 Impact factor: 12.701
Authors: Arnoud J Templeton; Carmel Pezaro; Aurelius Omlin; Mairéad G McNamara; Raya Leibowitz-Amit; Francisco E Vera-Badillo; Gerhardt Attard; Johann S de Bono; Ian F Tannock; Eitan Amir Journal: Cancer Date: 2014-07-03 Impact factor: 6.860
Authors: M Pichler; G C Hutterer; C Stoeckigt; T F Chromecki; T Stojakovic; S Golbeck; K Eberhard; A Gerger; S Mannweiler; K Pummer; R Zigeuner Journal: Br J Cancer Date: 2013-02-05 Impact factor: 7.640
Authors: W S Jang; K S Cho; K H Kim; C Y Yoon; Y J Kang; J Y Lee; W S Ham; K H Rha; S J Hong; Y D Choi Journal: Prostate Cancer Prostatic Dis Date: 2016-06-28 Impact factor: 5.554